Teprotumumab-trbw
What is Teprotumumab-trbw?[edit | edit source]
- Teprotumumab-trbw (TEPEZZA) is an insulin-like growth factor-1 receptor inhibitor.
What are the uses of this medicine?[edit | edit source]
- This medicine is used for the treatment of Thyroid Eye Disease.
How does this medicine work?[edit | edit source]
- Teprotumumab-trbw's mechanism of action in patients with Thyroid Eye Disease has not been fully characterized.
- Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling.
Who Should Not Use this medicine ?[edit | edit source]
- This medicine have no usage limitations.
Is this medicine FDA approved?[edit | edit source]
- It was approved for use in the United States in 2020.
How should this medicine be used?[edit | edit source]
Recommended Dosage
- The recommended dose of TEPEZZA is an intravenous infusion of 10 mg/kg for the initial dose followed by an intravenous infusion of 20 mg/kg every three weeks for 7 additional infusions.
Administration
- Administer the diluted solution intravenously over 90 minutes for the first two infusions.
- If well tolerated, the minimum time for subsequent infusions can be reduced to 60 minutes.
- If not well tolerated, the minimum time for subsequent infusions should remain at 90 minutes.
- Do not administer as an intravenous push or bolus.
- TEPEZZA should not be infused concomitantly with other agents.
What are the dosage forms and brand names of this medicine?[edit | edit source]
This medicine is available in fallowing doasage form:
- As Injection: 500 mg lyophilized powder in a single-dose vial for reconstitution
This medicine is available in fallowing brand namesː
- TEPEZZA
What side effects can this medication cause?[edit | edit source]
The most common side effects of this medicine include:
- muscle spasm
- nausea
- alopecia
- diarrhea
- fatigue
- hyperglycemia
- hearing impairment
- dry skin
- dysgeusia
- headache
What special precautions should I follow?[edit | edit source]
- Infusion reactions may occur.If an infusion reaction occurs, interrupt or slow the rate of infusion and use appropriate medical management.
- Monitor patients with preexisting Inflammatory Bowel Disease (IBD) for flare of disease; discontinue TEPEZZA if IBD worsens.
- This medicine may cause hyperglycemia.
- Monitor glucose levels in all patients; treat hyperglycemia with glycemic control medications.
What to do in case of emergency/overdose?[edit | edit source]
- No information is available for patients who have received an overdosage.
Can this medicine be used in pregnancy?[edit | edit source]
- There are insufficient data with TEPEZZA use in pregnant women to inform any drug associated risks for adverse developmental outcomes.
Can this medicine be used in children?[edit | edit source]
- Safety and effectiveness have not been established in pediatric patients.
What should I know about storage and disposal of this medication?[edit | edit source]
- Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton until time of use to protect from light. Do not freeze.
Teprotumumab-trbw Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Deepika vegiraju